首页 > 最新文献

Journal of vascular surgery. Venous and lymphatic disorders最新文献

英文 中文
Meta-analysis of duration of venous thromboembolism risk following hospitalization in surgical and medical patients 外科和内科患者住院后静脉血栓栓塞风险持续时间的meta分析。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-10-10 DOI: 10.1016/j.jvsv.2025.102343
Georges Jreij MD , Caroline Crone BS , Aidan Wiley BA , Aman Kankaria DO , Mary S. Lin MD , Minerva Mayorga-Carlin MPH , Shalini Sahoo MA , John D. Sorkin MD, PhD , Brajesh K. Lal MD

Objective

Hospitalization increases venous thromboembolism (VTE) risk, and over one-half of all VTE events occur after hospital admission. Current decisions on post-hospitalization VTE prophylaxis are not evidence-based. The duration of enhanced risk after hospitalization, in surgical and medical patients, is not well-known. In this meta-analysis, we evaluated the rates of post-hospitalization VTE over time in patients that underwent surgery during their hospitalization and those that did not.

Methods

A literature search was performed through November 2023 using PubMed, EMBASE, and Cochrane. Studies examining the incidence of VTE in hospitalized patients during a specified period following hospitalization were included. Studies were excluded if they focused on nonhospitalized patients, failed to define the follow-up duration, or did not report the incidence of VTE. Screening and data collection was conducted by two reviewers.

Results

From a total of 1504 studies screened, 57 were included. Overall, 9,152,616 patients were included; of these, 1,232,627 were followed for 30 days, 28,522 for 45 days, 2,515,940 for 90 days, and 5,375,527 were followed beyond 90 days. The pooled incidence of VTE during the first 45 days was 0.3% (95% confidence interval [CI], 0.2%- 0.4%) among surgical patients and 4.6% (95% CI, 4.3%-4.9%) among medical patients. The pooled incidence of VTE during the first 90 days was 1.3% (95% CI, 0.7%-2.3%) in surgical patients and 2.9% (95% CI, 2.0%-4.1%) in medical patients. Beyond 90 days (between 180 and 1020 days), the pooled incidence of VTE was 1.0% (95% CI, 0.4%-2.3%) in the surgical cohort, compared with 2.3% (95% CI, 1.6%-3.5%) in the medical cohort.

Conclusions

The post-hospitalization 90-day VTE rate was found to be low for both surgical and medical patients; the risks beyond 90 days was found to be only slightly lower. VTE risk in surgical patients is predominantly short-term and diminishes following recovery from surgery. Conversely, medical patients exhibit a prolonged VTE risk, likely related to persistence of clinical risk factors.
目的:住院增加静脉血栓栓塞的风险,超过一半的静脉血栓栓塞事件发生在住院后。目前关于住院后静脉血栓栓塞预防的决定是没有证据的。在外科和内科患者中,住院后风险增加的持续时间尚不清楚。在这项荟萃分析中,我们评估了住院期间接受手术和未接受手术的患者的住院后静脉血栓栓塞率。方法:通过PubMed、EMBASE和Cochrane检索到2023年11月的文献。研究纳入了住院患者在住院后特定时期内静脉血栓栓塞发生率的研究。如果研究集中于非住院患者,未能确定随访时间,或未报告静脉血栓栓塞的发生率,则排除研究。筛选和数据收集由两名审稿人进行。结果:在总共1504项研究中,57项被纳入。总体而言,纳入了9,152,616例患者;其中,30天随访12232627人,45天随访28522人,90天随访2515940人,90天以上随访5375527人。手术患者前45天静脉血栓栓塞总发生率为0.3%(95%可信区间[CI]: 0.2; 0.4),内科患者为4.6%(95%可信区间:4.3-4.9)。手术患者前90天内静脉血栓栓塞的总发生率为1.3% (95% CI: 0.7-2.3),内科患者为2.9% (95% CI: 2.0-4.1)。超过90天(180 - 1020天),手术组静脉血栓栓塞总发生率为1.0% (95% CI: 0.4-2.3),而医学组为2.3% (95% CI: 1.6-3.5)。结论:外科和内科患者住院后90天静脉血栓栓塞发生率均较低;超过90天的风险仅略低。手术患者的静脉血栓栓塞风险主要是短期的,并随着手术恢复而降低。相反,内科患者的静脉血栓栓塞风险延长,可能与临床风险因素的持续存在有关。
{"title":"Meta-analysis of duration of venous thromboembolism risk following hospitalization in surgical and medical patients","authors":"Georges Jreij MD ,&nbsp;Caroline Crone BS ,&nbsp;Aidan Wiley BA ,&nbsp;Aman Kankaria DO ,&nbsp;Mary S. Lin MD ,&nbsp;Minerva Mayorga-Carlin MPH ,&nbsp;Shalini Sahoo MA ,&nbsp;John D. Sorkin MD, PhD ,&nbsp;Brajesh K. Lal MD","doi":"10.1016/j.jvsv.2025.102343","DOIUrl":"10.1016/j.jvsv.2025.102343","url":null,"abstract":"<div><h3>Objective</h3><div>Hospitalization increases venous thromboembolism (VTE) risk, and over one-half of all VTE events occur after hospital admission. Current decisions on post-hospitalization VTE prophylaxis are not evidence-based. The duration of enhanced risk after hospitalization, in surgical and medical patients, is not well-known. In this meta-analysis, we evaluated the rates of post-hospitalization VTE over time in patients that underwent surgery during their hospitalization and those that did not.</div></div><div><h3>Methods</h3><div>A literature search was performed through November 2023 using PubMed, EMBASE, and Cochrane. Studies examining the incidence of VTE in hospitalized patients during a specified period following hospitalization were included. Studies were excluded if they focused on nonhospitalized patients, failed to define the follow-up duration, or did not report the incidence of VTE. Screening and data collection was conducted by two reviewers.</div></div><div><h3>Results</h3><div>From a total of 1504 studies screened, 57 were included. Overall, 9,152,616 patients were included; of these, 1,232,627 were followed for 30 days, 28,522 for 45 days, 2,515,940 for 90 days, and 5,375,527 were followed beyond 90 days. The pooled incidence of VTE during the first 45 days was 0.3% (95% confidence interval [CI], 0.2%- 0.4%) among surgical patients and 4.6% (95% CI, 4.3%-4.9%) among medical patients. The pooled incidence of VTE during the first 90 days was 1.3% (95% CI, 0.7%-2.3%) in surgical patients and 2.9% (95% CI, 2.0%-4.1%) in medical patients. Beyond 90 days (between 180 and 1020 days), the pooled incidence of VTE was 1.0% (95% CI, 0.4%-2.3%) in the surgical cohort, compared with 2.3% (95% CI, 1.6%-3.5%) in the medical cohort.</div></div><div><h3>Conclusions</h3><div>The post-hospitalization 90-day VTE rate was found to be low for both surgical and medical patients; the risks beyond 90 days was found to be only slightly lower. VTE risk in surgical patients is predominantly short-term and diminishes following recovery from surgery. Conversely, medical patients exhibit a prolonged VTE risk, likely related to persistence of clinical risk factors.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 1","pages":"Article 102343"},"PeriodicalIF":2.8,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical outcomes of above-knee versus full-length endovenous laser ablation for great saphenous vein varicose veins 膝上与全静脉内激光消融治疗大隐静脉曲张的疗效比较。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-10-10 DOI: 10.1016/j.jvsv.2025.102342
Yafei Zhang MS , Xiao Lin MN , Zihao Wang MS , Wentao Li MD , Yuqin Wang MN , Jing Bian MPH , Yong Liang MD

Objective

This study compares the surgical outcomes between endovenous laser ablation of the above-knee great saphenous vein (AK-GSV) and full-length great saphenous vein (FL-GSV) for the treatment of lower limb varicose veins.

Methods

This retrospective study analyzed clinical data from consecutive patients with lower extremity varicose veins treated at a tertiary vascular surgery center between November 2023 and December 2024. Participants were categorized into two groups based on surgical approach: the AK-GSV laser treatment group (n = 134) and the FL-GSV laser closure treatment group (n = 166). The study compared operative time, postoperative pain intensity, improvement in general symptoms, and incidence of saphenous nerve injury between the two groups.

Results

AK-GSV laser treatment was associated with shorter surgical duration (60.52 ± 8.26 minutes) compared with the FL- GSV laser treatment (64.01 ± 8.71 minutes; P = .000). Additionally, AK-GSV treatment was associated with milder early postoperative pain, as reflected by lower Visual Analogue Scale (VAS) scores at 1 day (2.82 ± 0.96 vs 3.14 ± 0.83; P = .002) and 3 days (1.57 ± 0.64 vs 1.77 ± 0.67; P =.01) postoperatively. The AK-GSV treatment group exhibited superior short-term outcomes, with significantly larger reductions in the Venous Clinical Severity Score (VCSS) (P = .009) and the Aberdeen Varicose Vein Questionnaire (AVVQ) score (P = .045) during the early postoperative period (within the first 1 month postoperatively) compared with the FL-GSV group. Compared with the FL-GSV treatment group, the AK-GSV group had a significantly lower incidence of saphenous nerve injury at 1 month (4.5% vs 15.7%; P = .002), 3 months (2.2% vs 8.4%; P = .021), and 9 months (0.0% vs 4.2%; P = .018). However, this intergroup difference was no longer statistically significant at 6 months (1.5% vs 5.4%; P = .072).

Conclusions

AK-GSV endovenous laser ablation is a safe and effective minimally invasive treatment approach. Compared with FL-GSV ablation, this technique demonstrates comparable efficacy in improving venous stasis symptoms while offering significant advantages, including reduced operative time, decreased postoperative pain, accelerated recovery, and lower risks of neurological complications.
目的:比较静脉内激光消融膝上大隐静脉(AK-GSV)与全长大隐静脉(FL-GSV)治疗下肢静脉曲张的手术效果。方法:回顾性分析2023年11月至2024年12月在某三级血管外科中心连续治疗的下肢静脉曲张患者的临床资料。根据手术入路将参与者分为两组:膝上GSV激光治疗组(AK-GSV, n = 134)和全长GSV激光闭合治疗组(FL-GSV, n = 166)。比较两组手术时间、术后疼痛强度、一般症状改善情况及隐神经损伤发生率。结果:AK-GSV激光治疗手术时间(60.52±8.26 min)短于FL- GSV激光治疗(64.01±8.71 min, P= 0.000)。此外,AK-GSV治疗与术后早期疼痛较轻相关,这反映在术后1天(2.82±0.96 vs 3.14±0.83,P = 0.002)和3天(1.57±0.64 vs 1.77±0.67,P = 0.01)的视觉模拟评分较低。与FL-GSV组相比,AK-GSV治疗组表现出较好的短期预后,术后早期(术后1个月内)静脉临床严重程度评分(VCSS) (P = 0.009)和阿伯丁静脉曲张问卷评分(AVVQ) (P = 0.045)的降低幅度明显大于FL-GSV组。与FL-GSV治疗组相比,AK-GSV组在1个月(4.5% vs 15.7%, P = 0.002)、3个月(2.2% vs 8.4%, P = 0.021)和9个月(0.0% vs 4.2%, P = 0.018)时的隐神经损伤发生率均显著降低。然而,在6个月时,组间差异不再具有统计学意义(1.5% vs 5.4%, P = 0.072)。结论:AK-GSV静脉内激光消融(EVLA)是一种安全有效的微创治疗方法。与FL-GSV消融相比,该技术在改善静脉淤滞症状方面具有相当的疗效,同时具有显著的优势,包括缩短手术时间、减少术后疼痛、加速恢复和降低神经系统并发症的风险。
{"title":"Surgical outcomes of above-knee versus full-length endovenous laser ablation for great saphenous vein varicose veins","authors":"Yafei Zhang MS ,&nbsp;Xiao Lin MN ,&nbsp;Zihao Wang MS ,&nbsp;Wentao Li MD ,&nbsp;Yuqin Wang MN ,&nbsp;Jing Bian MPH ,&nbsp;Yong Liang MD","doi":"10.1016/j.jvsv.2025.102342","DOIUrl":"10.1016/j.jvsv.2025.102342","url":null,"abstract":"<div><h3>Objective</h3><div>This study compares the surgical outcomes between endovenous laser ablation of the above-knee great saphenous vein (AK-GSV) and full-length great saphenous vein (FL-GSV) for the treatment of lower limb varicose veins.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed clinical data from consecutive patients with lower extremity varicose veins treated at a tertiary vascular surgery center between November 2023 and December 2024. Participants were categorized into two groups based on surgical approach: the AK-GSV laser treatment group (n = 134) and the FL-GSV laser closure treatment group (n = 166). The study compared operative time, postoperative pain intensity, improvement in general symptoms, and incidence of saphenous nerve injury between the two groups.</div></div><div><h3>Results</h3><div>AK-GSV laser treatment was associated with shorter surgical duration (60.52 ± 8.26 minutes) compared with the FL- GSV laser treatment (64.01 ± 8.71 minutes; <em>P</em> = .000). Additionally, AK-GSV treatment was associated with milder early postoperative pain, as reflected by lower Visual Analogue Scale (VAS) scores at 1 day (2.82 ± 0.96 vs 3.14 ± 0.83; <em>P</em> = .002) and 3 days (1.57 ± 0.64 vs 1.77 ± 0.67; <em>P</em> =.01) postoperatively. The AK-GSV treatment group exhibited superior short-term outcomes, with significantly larger reductions in the Venous Clinical Severity Score (VCSS) (<em>P</em> = .009) and the Aberdeen Varicose Vein Questionnaire (AVVQ) score (<em>P</em> = .045) during the early postoperative period (within the first 1 month postoperatively) compared with the FL-GSV group. Compared with the FL-GSV treatment group, the AK-GSV group had a significantly lower incidence of saphenous nerve injury at 1 month (4.5% vs 15.7%; <em>P</em> = .002), 3 months (2.2% vs 8.4%; <em>P</em> = .021), and 9 months (0.0% vs 4.2%; <em>P</em> = .018). However, this intergroup difference was no longer statistically significant at 6 months (1.5% vs 5.4%; <em>P</em> = .072).</div></div><div><h3>Conclusions</h3><div>AK-GSV endovenous laser ablation is a safe and effective minimally invasive treatment approach. Compared with FL-GSV ablation, this technique demonstrates comparable efficacy in improving venous stasis symptoms while offering significant advantages, including reduced operative time, decreased postoperative pain, accelerated recovery, and lower risks of neurological complications.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 1","pages":"Article 102342"},"PeriodicalIF":2.8,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thigh lymphocutaneous fistula in a child 儿童大腿淋巴皮瘘。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-10-09 DOI: 10.1016/j.jvsv.2025.102341
Qi Di MD , Kai Zheng MD , Qiang-Qiang Nie PhD , San-Lin Li MD , Cheng-Hao Chen MD , Gang Shen MD
{"title":"Thigh lymphocutaneous fistula in a child","authors":"Qi Di MD ,&nbsp;Kai Zheng MD ,&nbsp;Qiang-Qiang Nie PhD ,&nbsp;San-Lin Li MD ,&nbsp;Cheng-Hao Chen MD ,&nbsp;Gang Shen MD","doi":"10.1016/j.jvsv.2025.102341","DOIUrl":"10.1016/j.jvsv.2025.102341","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 1","pages":"Article 102341"},"PeriodicalIF":2.8,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spontaneous saccular aneurysm of the external jugular vein with thrombosis 颈外静脉自发性囊性动脉瘤伴血栓形成。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-10-09 DOI: 10.1016/j.jvsv.2025.102339
Zhuoyuan Li MD, MSc , Tan Li MD
{"title":"Spontaneous saccular aneurysm of the external jugular vein with thrombosis","authors":"Zhuoyuan Li MD, MSc ,&nbsp;Tan Li MD","doi":"10.1016/j.jvsv.2025.102339","DOIUrl":"10.1016/j.jvsv.2025.102339","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 1","pages":"Article 102339"},"PeriodicalIF":2.8,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of gynecological disorders in women with symptomatic pelvic venous disorders 有症状的盆腔静脉疾病妇女的妇科疾病患病率。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-10-09 DOI: 10.1016/j.jvsv.2025.102338
Syona Satwah MD, Natalie Ma, Theresa Soto MD, Gaurav Lakhanpal MD, Richard Kennedy PAC, Sanjiv Lakhanpal MD, Peter J. Pappas MD

Background

The diagnosis of symptomatic pelvic venous insufficiency (PVI) in women is complicated when concomitant gynecological disorders are present. The purpose of this investigation was to determine the prevalence of concomitant gynecological disorders in women with a pelvic venous disorder secondary to PVI and to assess the effectiveness of therapeutic interventions in women with a history of these disorders.

Methods

We retrospectively reviewed the results of 2544 women treated for symptomatic PVI from January 2017 to March 2024. Women were divided in three groups: pelvic pain alone, leg pain alone or combined pelvic and leg pain (mixed). Patient demographics, prevalence of concomitant gynecological disorders, presenting symptoms, Clinical, Etiology, Anatomy, Pathophysiology class, rVCSS, pre and post visual analog pain scores (VAS), stent type, and vein territory covered were assessed.

Results

Of the 2544 women, 70 presented with pelvic pain alone, 1012 with leg pain alone, and 1454 with mixed symptoms. The average age of the cohort was 52.0 ± 13.8 years. Racial distribution was 49% White, 16% African American, 11% Hispanic, 1% Asian, and 23% unknown. The most common gynecological disorders reported were hysterectomy (31%), uterine fibroids (4%), endometriosis (4.4%), ovarian cysts (2.8%), and polycystic ovarian syndrome (1.5%). The average follow-up time was 2.32 ± 2.4 years. Pre and post intervention VAS scores were pelvic (7.61 ± 3.72/1.93 ± 3.2), leg (6.18 ± 2.95/2.42 ± 3.2), and mixed (5.72 ± 3.72/2.4 ± 3.1) (P ≤ .05). For women with a history of endometriosis, pre and post VAS scores were 6.52 ± 3.15 and 2.5 ± 0.6 (P ≤ .05). There was no difference in pre and post VAS scores in women with a history of endometriosis compared with the other presenting symptom groups. A total of 1738 stents were placed: 27 pelvic, 564 leg, and 935 mixed. The most common stent diameters and lengths were 14 and 16 mm and 140 and 160 mm. The left common and external iliac veins were the most common vein territories covered. There were 768 reinterventions for a 25.6% reintervention rate at 25 ± 24 months.

Conclusions

The prevalence of concomitant gynecological disorders in women with symptomatic PVI is very low and calls into question whether or not gynecological assessments for etiologies other than PVI are necessary. Even in women with a history of endometriosis, endovascular interventions are very successful at ameliorating pelvic and/or leg symptoms. A history of concomitant gynecological disorders should not prevent the performance of endovascular therapies in women with symptomatic PVI.
导言:女性盆腔静脉功能不全(PVI)的诊断是复杂的,当同时存在妇科疾病。本研究的目的是确定继发于PVI的PeVD女性伴发妇科疾病的患病率,并评估有这些疾病史的女性的治疗干预措施的有效性。方法:我们回顾性分析了2017年1月至2024年3月期间治疗症状性PVI的2544名女性的结果。女性被分成三组。单独骨盆疼痛、单独腿部疼痛或骨盆和腿部合并疼痛(混合性)。评估患者人口统计学特征、伴发妇科疾病的患病率、出现症状、CEAP、rVCSS、视觉模拟疼痛评分(VAS)前后、支架类型和静脉覆盖范围。结果:在2544名女性中,70名仅表现为盆腔疼痛,1012名仅表现为腿部疼痛,1454名表现为混合症状。队列的平均年龄为52±13.8岁。种族分布如下:白人49%,非裔美国人16%,西班牙裔11%,亚裔1%,未知23%。最常见的妇科疾病是子宫切除术(31%)、子宫肌瘤(4%)、子宫内膜异位症(4.4%)、卵巢囊肿(2.8%)和多囊卵巢(1.5%)。平均随访时间为2.32±2.4年。干预前后视觉模拟疼痛(VAS)评分分别为:盆腔(7.61±3.72/1.93±3.2)、腿部(6.18±2.95/2.42±3.2)、混合(5.72±3.72/2.4±3.1)(p≤0.05)。有子宫内膜异位症病史的女性VAS评分分别为:6.52±3.15和2.5±0.6 (p≤0.05)。有子宫内膜异位症病史的女性与其他症状组相比,VAS评分前后无差异。总共放置了1738个支架:骨盆(n=27),腿部(n=564)和混合(n=935)。最常见的支架直径和长度分别为14和16毫米(mm)以及140和160毫米。左髂总静脉和髂外静脉是最常见的静脉区域。在25±24个月,再干预768例,再干预率为25.6%。结论:在有症状的PVI女性中,伴随妇科疾病的患病率非常低,这引起了对PVI以外的病因是否有必要进行妇科评估的疑问。即使在有子宫内膜异位症病史的女性中,血管内介入治疗在改善盆腔和/或腿部症状方面也非常成功。伴有妇科疾病的病史不应妨碍有症状性PVI的妇女进行血管内治疗。
{"title":"Prevalence of gynecological disorders in women with symptomatic pelvic venous disorders","authors":"Syona Satwah MD,&nbsp;Natalie Ma,&nbsp;Theresa Soto MD,&nbsp;Gaurav Lakhanpal MD,&nbsp;Richard Kennedy PAC,&nbsp;Sanjiv Lakhanpal MD,&nbsp;Peter J. Pappas MD","doi":"10.1016/j.jvsv.2025.102338","DOIUrl":"10.1016/j.jvsv.2025.102338","url":null,"abstract":"<div><h3>Background</h3><div>The diagnosis of symptomatic pelvic venous insufficiency (PVI) in women is complicated when concomitant gynecological disorders are present. The purpose of this investigation was to determine the prevalence of concomitant gynecological disorders in women with a pelvic venous disorder secondary to PVI and to assess the effectiveness of therapeutic interventions in women with a history of these disorders.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the results of 2544 women treated for symptomatic PVI from January 2017 to March 2024. Women were divided in three groups: pelvic pain alone, leg pain alone or combined pelvic and leg pain (mixed). Patient demographics, prevalence of concomitant gynecological disorders, presenting symptoms, Clinical, Etiology, Anatomy, Pathophysiology class, rVCSS, pre and post visual analog pain scores (VAS), stent type, and vein territory covered were assessed.</div></div><div><h3>Results</h3><div>Of the 2544 women, 70 presented with pelvic pain alone, 1012 with leg pain alone, and 1454 with mixed symptoms. The average age of the cohort was 52.0 ± 13.8 years. Racial distribution was 49% White, 16% African American, 11% Hispanic, 1% Asian, and 23% unknown. The most common gynecological disorders reported were hysterectomy (31%), uterine fibroids (4%), endometriosis (4.4%), ovarian cysts (2.8%), and polycystic ovarian syndrome (1.5%). The average follow-up time was 2.32 ± 2.4 years. Pre and post intervention VAS scores were pelvic (7.61 ± 3.72/1.93 ± 3.2), leg (6.18 ± 2.95/2.42 ± 3.2), and mixed (5.72 ± 3.72/2.4 ± 3.1) (<em>P</em> ≤ .05). For women with a history of endometriosis, pre and post VAS scores were 6.52 ± 3.15 and 2.5 ± 0.6 (<em>P</em> ≤ .05). There was no difference in pre and post VAS scores in women with a history of endometriosis compared with the other presenting symptom groups. A total of 1738 stents were placed: 27 pelvic, 564 leg, and 935 mixed. The most common stent diameters and lengths were 14 and 16 mm and 140 and 160 mm. The left common and external iliac veins were the most common vein territories covered. There were 768 reinterventions for a 25.6% reintervention rate at 25 ± 24 months.</div></div><div><h3>Conclusions</h3><div>The prevalence of concomitant gynecological disorders in women with symptomatic PVI is very low and calls into question whether or not gynecological assessments for etiologies other than PVI are necessary. Even in women with a history of endometriosis, endovascular interventions are very successful at ameliorating pelvic and/or leg symptoms. A history of concomitant gynecological disorders should not prevent the performance of endovascular therapies in women with symptomatic PVI.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 1","pages":"Article 102338"},"PeriodicalIF":2.8,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iatrogenic superficial femoral arteriovenous fistula and pseudoaneurysm 医源性浅股动静脉瘘和假性动脉瘤。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-10-02 DOI: 10.1016/j.jvsv.2025.102335
Xu Li MD , Juan Yang MD , Hua Yi Zhang MD
{"title":"Iatrogenic superficial femoral arteriovenous fistula and pseudoaneurysm","authors":"Xu Li MD ,&nbsp;Juan Yang MD ,&nbsp;Hua Yi Zhang MD","doi":"10.1016/j.jvsv.2025.102335","DOIUrl":"10.1016/j.jvsv.2025.102335","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 1","pages":"Article 102335"},"PeriodicalIF":2.8,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stewart-Treves syndrome: A rare complication of lymphedema 斯图尔特-特里夫斯综合征:一种罕见的淋巴水肿并发症。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-10-01 DOI: 10.1016/j.jvsv.2025.102336
Marta Machado MD, Miguel Machado MD, Arlindo Matos MD, Rui Machado PhD
{"title":"Stewart-Treves syndrome: A rare complication of lymphedema","authors":"Marta Machado MD,&nbsp;Miguel Machado MD,&nbsp;Arlindo Matos MD,&nbsp;Rui Machado PhD","doi":"10.1016/j.jvsv.2025.102336","DOIUrl":"10.1016/j.jvsv.2025.102336","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 1","pages":"Article 102336"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complex decongestive therapy combined with needle electrode stimulation facilitates postoperative rehabilitation of lymphedema 综合减充血治疗结合针电极刺激有助于术后淋巴水肿的康复。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-10-01 DOI: 10.1016/j.jvsv.2025.102337
Qiong Wu BS , Longxin An BS , Li Xu BS , Wen Zhou BS , Xiaojing Li BS , Longfei Liu BS , Qi Tan MS , Xuecheng Sun MS , Naibo Feng MD

Objective

To evaluate the clinical efficacy of complex decongestive therapy (CDT) combined with needle electrode stimulation (NES) in the management of lymphedema after lymphaticovenular anastomosis (LVA) and to compare its therapeutic outcomes with conventional CDT alone.

Methods

A retrospective analysis was conducted on 50 patients with secondary lymphedema who underwent LVA at the Department of Traumatic Orthopedics, Weifang People's Hospital, between June 2023 and June 2024. All patients met strict inclusion criteria and were randomly assigned to one of two groups: group A (CDT combined with NES; n = 25; 3 males, 22 females) and group B (CDT alone; n = 25; 3 males, 22 females). There was no significant difference in sex distribution between groups (χ2 = 0.00; P > .99), indicating baseline comparability.

Results

No significant main effect of group was observed for limb swelling rate (P = .46; n = 50), indicating comparable overall swelling levels between groups. A significant main effect of time was found across all timepoints (preoperatively and at 2 weeks, 1 month, 3 months, 6 months, and 12 months postoperatively; P < .01; n = 25), suggesting a general decrease in swelling over time. Importantly, a significant group × time interaction was identified (P = .03; n = 25), indicating that the rate of decrease in swelling differed, with group A showing a greater and faster improvement. For quality of life assessed by the Lymphedema Life Impact Scale (LLIS), the between-group difference was not statistically significant (P = .09; n = 25). However, a significant time effect was observed (P < .01), and a significant group × time interaction (P = .02) indicated a more favorable trajectory in group A. No adverse events, including infection, poor wound healing, or cellulitis, were reported during the study.

Conclusions

CDT combined with NES demonstrates superior efficacy in decreasing limb swelling and improving Lymphedema Life Impact Scale scores compared with CDT alone in the postoperative management of lymphedema after LVA. This combination therapy significantly enhances postoperative recovery, suggesting its potential as a more effective approach for lymphedema rehabilitation.
目的:评价综合减充血疗法(CDT)联合针电极刺激治疗淋巴小囊吻合(LVA)后淋巴水肿的临床疗效,并与单纯常规减充血疗法的疗效进行比较。方法:回顾性分析潍坊市人民医院创伤骨科于2023年6月至2024年6月行淋巴静脉吻合术(LVA)的继发性淋巴水肿患者50例。所有患者均符合严格的纳入标准,随机分为两组:A组(CDT联合针电极刺激,n = 25,男3,女22)和B组(CDT单独治疗,n = 25,男3,女22)。各组间性别分布差异无统计学意义(χ2 = 0.00, p < 0.99),具有基线可比性。结果:各组肢体肿胀率无显著主效应(p = 0.46, N = 50),各组整体肿胀水平相当。时间在所有时间点(术前、术后2周、1个月、3个月、6个月和12个月;p < 0.01, N = 25)均有显著的主要影响,表明肿胀随时间的推移普遍减轻。重要的是,发现了显著的组与时间交互作用(p = 0.03, N = 25),表明肿胀减轻的速度不同,a组的改善更大更快。以淋巴水肿生活影响量表(LLIS)评估的生活质量,组间差异无统计学意义(p = 0.09, N = 25)。然而,观察到显著的时间效应(p < 0.01),并且显著的组×时间相互作用(p = 0.02)表明a组的发展轨迹更有利,在研究期间没有报告不良事件,包括感染,伤口愈合不良或蜂窝织炎。结论:CDT联合针电极刺激在减轻肢体肿胀和提高LLIS评分方面优于CDT单独治疗LVA术后淋巴水肿。这种联合治疗显著提高术后恢复,提示其作为淋巴水肿康复的更有效方法的潜力。
{"title":"Complex decongestive therapy combined with needle electrode stimulation facilitates postoperative rehabilitation of lymphedema","authors":"Qiong Wu BS ,&nbsp;Longxin An BS ,&nbsp;Li Xu BS ,&nbsp;Wen Zhou BS ,&nbsp;Xiaojing Li BS ,&nbsp;Longfei Liu BS ,&nbsp;Qi Tan MS ,&nbsp;Xuecheng Sun MS ,&nbsp;Naibo Feng MD","doi":"10.1016/j.jvsv.2025.102337","DOIUrl":"10.1016/j.jvsv.2025.102337","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the clinical efficacy of complex decongestive therapy (CDT) combined with needle electrode stimulation (NES) in the management of lymphedema after lymphaticovenular anastomosis (LVA) and to compare its therapeutic outcomes with conventional CDT alone.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on 50 patients with secondary lymphedema who underwent LVA at the Department of Traumatic Orthopedics, Weifang People's Hospital, between June 2023 and June 2024. All patients met strict inclusion criteria and were randomly assigned to one of two groups: group A (CDT combined with NES; n = 25; 3 males, 22 females) and group B (CDT alone; n = 25; 3 males, 22 females). There was no significant difference in sex distribution between groups (χ<sup>2</sup> = 0.00; <em>P</em> &gt; .99), indicating baseline comparability.</div></div><div><h3>Results</h3><div>No significant main effect of group was observed for limb swelling rate (<em>P</em> = .46; n = 50), indicating comparable overall swelling levels between groups. A significant main effect of time was found across all timepoints (preoperatively and at 2 weeks, 1 month, 3 months, 6 months, and 12 months postoperatively; <em>P</em> &lt; .01; n = 25), suggesting a general decrease in swelling over time. Importantly, a significant group × time interaction was identified (<em>P</em> = .03; n = 25), indicating that the rate of decrease in swelling differed, with group A showing a greater and faster improvement. For quality of life assessed by the Lymphedema Life Impact Scale (LLIS), the between-group difference was not statistically significant (<em>P</em> = .09; n = 25). However, a significant time effect was observed (<em>P</em> &lt; .01), and a significant group × time interaction (<em>P</em> = .02) indicated a more favorable trajectory in group A. No adverse events, including infection, poor wound healing, or cellulitis, were reported during the study.</div></div><div><h3>Conclusions</h3><div>CDT combined with NES demonstrates superior efficacy in decreasing limb swelling and improving Lymphedema Life Impact Scale scores compared with CDT alone in the postoperative management of lymphedema after LVA. This combination therapy significantly enhances postoperative recovery, suggesting its potential as a more effective approach for lymphedema rehabilitation.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 1","pages":"Article 102337"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy for the treatment of C1 and C2 patients with a new method hemodynamic hybrid Nd YAG 1064 LASER and cryosclerotherapy 血液动力学混合Nd YAG 1064激光和冷冻硬化治疗(HHLCS)治疗C1-C2患者的安全性和有效性。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-09-30 DOI: 10.1016/j.jvsv.2025.102320
Cláudia Carvalho Sathler de Melo MD , Felipe Puricelli Faccini MD, MSc

Objective

To evaluate the safety and efficacy of hemodynamic hybrid LASER cryosclerotherapy for the treatment of chronic venous disease in patients with telangiectasias, reticular veins, and varicose veins.

Methods

This retrospective cohort included patients classified as C1 and C2 low treated between February 2022 and November 2024. A total of 41 women were included. All patients underwent clinical evaluation, Doppler ultrasound venous mapping for evidence of deep and superficial reflux and standardized pretreatment and post-treatment photography. Exclusion criteria included previous saphenous treatment, thromboembolic events, and Fitzpatrick skin type VI. We used YAG Laser and cooled 67% to 75% dextrose injection.

Results

A total of 71 treatment sessions were performed. Lesion clearance was categorized as insufficient (<50%), moderate (50%-69%), or complete (70%-100%) based on photographic comparison by the treating physician and patient consensus. Complete clearance was achieved in 83% of patients (34/41). Postinflammatory hyperpigmentation was the most common complication, with no cases of skin necrosis. Two minor thrombotic events were observed. No allergic reactions were reported.

Conclusions

Hemodynamic hybrid LASER cryosclerotherapy appears to be a safe and effective office-based treatment for C1 and C2 low patients, potentially reducing the need for invasive saphenous vein procedures in early-stage chronic venous disease.
目的:评价血液动力学混合激光冷冻硬化疗法(hlcs)治疗毛细血管扩张、网状静脉和静脉曲张患者的安全性和有效性。方法:该回顾性队列包括2022年2月至2024年11月期间接受治疗的C1和C2“低”患者。共有41名妇女被纳入研究。所有患者均接受了临床评估,多普勒超声静脉测绘(DUVM)以确定深层和浅表反流的证据,并进行了标准化的治疗前后摄影。排除标准包括既往隐静脉治疗、血栓栓塞事件和Fitzpatrick皮肤VI型。我们使用YAG激光和67-75%冷却葡萄糖注射液。结果:共进行了71次治疗。病变清除率被归类为不足(结论:HHLCS对于C1和C2“低”患者似乎是一种安全有效的基于办公室的治疗方法,可能减少早期CVD侵入性隐静脉手术的需要。
{"title":"Safety and efficacy for the treatment of C1 and C2 patients with a new method hemodynamic hybrid Nd YAG 1064 LASER and cryosclerotherapy","authors":"Cláudia Carvalho Sathler de Melo MD ,&nbsp;Felipe Puricelli Faccini MD, MSc","doi":"10.1016/j.jvsv.2025.102320","DOIUrl":"10.1016/j.jvsv.2025.102320","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the safety and efficacy of hemodynamic hybrid LASER cryosclerotherapy for the treatment of chronic venous disease in patients with telangiectasias, reticular veins, and varicose veins.</div></div><div><h3>Methods</h3><div>This retrospective cohort included patients classified as C1 and C2 low treated between February 2022 and November 2024. A total of 41 women were included. All patients underwent clinical evaluation, Doppler ultrasound venous mapping for evidence of deep and superficial reflux and standardized pretreatment and post-treatment photography. Exclusion criteria included previous saphenous treatment, thromboembolic events, and Fitzpatrick skin type VI. We used YAG Laser and cooled 67% to 75% dextrose injection.</div></div><div><h3>Results</h3><div>A total of 71 treatment sessions were performed. Lesion clearance was categorized as insufficient (&lt;50%), moderate (50%-69%), or complete (70%-100%) based on photographic comparison by the treating physician and patient consensus. Complete clearance was achieved in 83% of patients (34/41). Postinflammatory hyperpigmentation was the most common complication, with no cases of skin necrosis. Two minor thrombotic events were observed. No allergic reactions were reported.</div></div><div><h3>Conclusions</h3><div>Hemodynamic hybrid LASER cryosclerotherapy appears to be a safe and effective office-based treatment for C1 and C2 low patients, potentially reducing the need for invasive saphenous vein procedures in early-stage chronic venous disease.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 1","pages":"Article 102320"},"PeriodicalIF":2.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical treatment of perineal lymphatic malformations: A single-center retrospective study of 24 years 会阴淋巴畸形的手术治疗:一项24年单中心回顾性研究。
IF 2.8 2区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-09-26 DOI: 10.1016/j.jvsv.2025.102328
Pingping Liu MD , Yilong Guo MD , Ning Ma MD , Sen Chen MD , Yan Cao MD , Zhe Yang MD , Yangqun Li MD

Objective

To evaluate the long-term outcomes and recurrence patterns of surgical treatment for perineal lymphatic malformations (LMs), which are rare but functionally and cosmetically disabling.

Methods

We conducted a retrospective review of 19 patients with perineal LMs who underwent surgical excision between 2000 and 2024. All patients were followed for at least 1 year. Clinical presentation, surgical details, complications, and recurrences were analyzed. Recurrence-free survival was estimated using the Kaplan-Meier method, and risk factors were explored using univariate analysis.

Results

The cohort included 17 males and 2 females. Lesions were primarily located on the penis and scrotum. Symptoms included local swelling, disfigurement, cutaneous masses, lymphostatic elephantiasis, pain, skin discoloration, and functional compromise. No patients underwent surgery at 0 to 1 year of age, six were treated at 1 to 6 years, one at 6 to 12 years, six at 12 to 18 years, and six as adults (>18 years). The median follow-up duration was 12 years (range, 1-24 years). All skin grafts and flaps survived, and patient-reported functional and cosmetic outcomes improved significantly. The complication rate was 26.3%, including wound dehiscence, lymphatic leakage, and hypertrophic scars. Overall patient satisfaction was 84.2%. Primary surgical success (no recurrence after one procedure) was achieved in 63.2% of cases. Seven patients experienced recurrence. The estimated 20-year recurrence-free survival was 42.3%. Lymphostatic elephantiasis was significantly associated with recurrence (P < .05).

Conclusions

Surgical excision of perineal LMs is safe and effective. Most patients achieved lasting symptom relief and cosmetic benefits after one operation. However, recurrence is a long-term concern, highlighting the need for ongoing surveillance.
目的:探讨会阴淋巴畸形(LMs)手术治疗的远期疗效和复发模式。方法:我们对2000年至2024年间接受手术切除的19例会阴LMs患者进行了回顾性分析。所有患者随访至少1年。分析临床表现、手术细节、并发症及复发情况。使用Kaplan-Meier法估计无复发生存率,并使用单因素分析探讨危险因素。结果:该队列包括17名男性和2名女性。病变主要位于阴茎和阴囊;症状包括局部肿胀、畸形、皮肤肿块、淋巴性象皮病、疼痛、皮肤变色和功能损害。0-1岁时没有患者接受手术,6例在1-6岁时接受手术,1例在6-12岁时接受手术,6例在12-18岁时接受手术,6例为成人(bbb18岁)。中位随访时间为12年(范围:1-24年)。所有的皮肤移植物和皮瓣都存活了下来,患者报告的功能和美容结果显著改善。并发症发生率为26.3%,包括创面裂开、淋巴渗漏、增生性瘢痕。患者总体满意度为84.2%。63.2%的病例获得了初步手术成功(一次手术后无复发)。7例复发。估计20年无复发生存率为42.3%。结论:手术切除会阴象皮瘤是安全有效的。大多数患者在一次手术后获得了持久的症状缓解和美容效果。然而,复发是一个长期问题,因此需要持续监测。
{"title":"Surgical treatment of perineal lymphatic malformations: A single-center retrospective study of 24 years","authors":"Pingping Liu MD ,&nbsp;Yilong Guo MD ,&nbsp;Ning Ma MD ,&nbsp;Sen Chen MD ,&nbsp;Yan Cao MD ,&nbsp;Zhe Yang MD ,&nbsp;Yangqun Li MD","doi":"10.1016/j.jvsv.2025.102328","DOIUrl":"10.1016/j.jvsv.2025.102328","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the long-term outcomes and recurrence patterns of surgical treatment for perineal lymphatic malformations (LMs), which are rare but functionally and cosmetically disabling.</div></div><div><h3>Methods</h3><div>We conducted a retrospective review of 19 patients with perineal LMs who underwent surgical excision between 2000 and 2024. All patients were followed for at least 1 year. Clinical presentation, surgical details, complications, and recurrences were analyzed. Recurrence-free survival was estimated using the Kaplan-Meier method, and risk factors were explored using univariate analysis.</div></div><div><h3>Results</h3><div>The cohort included 17 males and 2 females. Lesions were primarily located on the penis and scrotum. Symptoms included local swelling, disfigurement, cutaneous masses, lymphostatic elephantiasis, pain, skin discoloration, and functional compromise. No patients underwent surgery at 0 to 1 year of age, six were treated at 1 to 6 years, one at 6 to 12 years, six at 12 to 18 years, and six as adults (&gt;18 years). The median follow-up duration was 12 years (range, 1-24 years). All skin grafts and flaps survived, and patient-reported functional and cosmetic outcomes improved significantly. The complication rate was 26.3%, including wound dehiscence, lymphatic leakage, and hypertrophic scars. Overall patient satisfaction was 84.2%. Primary surgical success (no recurrence after one procedure) was achieved in 63.2% of cases. Seven patients experienced recurrence. The estimated 20-year recurrence-free survival was 42.3%. Lymphostatic elephantiasis was significantly associated with recurrence (<em>P</em> &lt; .05).</div></div><div><h3>Conclusions</h3><div>Surgical excision of perineal LMs is safe and effective. Most patients achieved lasting symptom relief and cosmetic benefits after one operation. However, recurrence is a long-term concern, highlighting the need for ongoing surveillance.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 1","pages":"Article 102328"},"PeriodicalIF":2.8,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of vascular surgery. Venous and lymphatic disorders
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1